Fabian Gonell

Fabian Gonell is Senior Vice President, Licensing Strategy and Legal Counsel of Qualcomm’s Technology Licensing division, where his responsibilities include developing the Company’s licensing strategy, negotiating license agreements, and overseeing the company’s compliance with the rules of standards organizations. He has played a major role in structuring and negotiating license agreements with many of Qualcomm’s licensees, including Apple, Samsung, LGE, Ericsson, and Nokia/Microsoft, as well as in Qualcomm’s response to regulatory investigations of Qualcomm’s licensing practices.

Prior to joining Qualcomm, Mr. Gonell was a litigator at Cravath, Swaine & Moore LLP in New York, where he represented Qualcomm and other clients in patent and antitrust litigation. He also served as an adjunct professor at the Fordham University School of Law, where he taught courses in interviewing, counseling and negotiation. Mr. Gonell holds a BA in Economics from the City University of New York and a JD from the Fordham University School of Law, where he was Editor-in-Chief of the Fordham Law Review.

Securing the Future of the U.S. Biopharmaceutical Industry: The Most-Favored-Nation Paradox

By Sujai Shivakumar and Anne Pritchett The Trump administration is pursuing lowering prescription drug costs primarily to end what it describes as “global freeloading” and to ensure U.S. patients pay prices comparable to those in other developed nations. The administration argues that while the United States represents less than 5 percent
Read More

Universities, Patents, and the Future of U.S. Competitiveness

By Shruti Sharma and Chris Borges Universities are among the most powerful engines of U.S. innovation, transforming federal research investments into scientific discoveries that underpin economic growth, technological leadership, and national security. Current law, via the Bayh-Dole Act, allows universities to patent inventions and license them to private companies, with royalties
Read More

How Counterfeit Drugs Threaten U.S. Health and Innovation

By Anne Pritchett According to the Department of Homeland Security, counterfeit drugs “threaten national security and public safety directly when introduced into government and critical infrastructure supply chains, and indirectly if used to generate revenue for transnational criminal organizations.” Furthermore, counterfeit drugs harm pharmaceutical innovation by eroding profitability and investor
Read More